Safety and efficacy of 0.6 mg/kg rt-PA: Optimum rt-PA dose revisited

Etsuro Mori

Research output: Contribution to journalArticlepeer-review

9 Citations (Scopus)


Although the internationally recommended dosage of alteplase, a single-chain rt-PA, is 0.9 mg/kg, 0.6 mg/kg is the only approved dosage in Japan, and it is widely used there. Duteplase is a two-chain rt-PA, and based on findings of the duteplase trials in the early 1990s, the smaller dosage of 0.6 mg/kg of alteplase was tested in the Japan Alteplase Clinical Trial (J-ACT), which indicated that the efficacy/safety profile of this dose was comparable to the 0.9 mg/kg dosage used in other countries. The Japan Alteplase Clinical Trial II (J-ACT II) further demonstrated efficacy of 0.6 mg/kg alteplase with regard to vascular outcomes in patients with middle cerebral artery (MCA) occlusion. Finally, the Japan post-Marketing Alteplase Registration Study (J-MARS) confirmed the efficacy/safety profile of 0.6 mg/kg alteplase in a clinical setting that was comparable to the dose of 0.9 mg/kg in the European counterpart, the Safe Implementation of Thrombolysis in Stroke-Monitoring Study (SITS-MOST). The dose of 0.6 mg/kg seems to be optimal, at least in far-east Asians, and might be extrapolated to other ethnic groups as well.

Original languageEnglish
Pages (from-to)108-112
Number of pages5
JournalAnnals of the New York Academy of Sciences
Issue number1
Publication statusPublished - 2012 Sept


  • Acute ischemic stroke
  • Alteplase
  • Optimum dose
  • Recombinant tissue plasminogen activator
  • Thrombolytic therapy

ASJC Scopus subject areas

  • Neuroscience(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • History and Philosophy of Science


Dive into the research topics of 'Safety and efficacy of 0.6 mg/kg rt-PA: Optimum rt-PA dose revisited'. Together they form a unique fingerprint.

Cite this